Project 170396

The Role of the Inflammasome in Renal Injury

170396

The Role of the Inflammasome in Renal Injury

$512,080
Project Information
Study Type: Trial Randomized_Controlled_Trial
Therapeutic Area: Psychiatry
Research Theme: Biomedical
Disease Area: major depressive disorder
Data Type: Canadian
Institution & Funding
Principal Investigator(s): Muruve, Daniel A
Institution: University of Calgary
CIHR Institute: Infection and Immunity
Program: Operating Grant
Peer Review Committee: Experimental Medicine
Competition Year: 2008
Term: 4 yrs 0 mth
Abstract Summary

Kidney diseases are common in the general population. Many types of kidney disease are caused by toxins, poor circulation, diabetes and other insults. Invariably, these types of kidney injury result in either acute or chronic kidney failure which has a significant impact on patient health. When kidneys become injured, a significant component of inflammation is involved. It is known that inflammation that occurs during injury contributes to kidney failure resulting in a worse outcome. We have recently identified a new pathway of inflammation in the cell. We believe that this inflammatory pathway (called the inflammasome)is activated by the types of injury stated above such as poor circulation or toxins. The activation of the inflammasome contributes to the severity of the kidney injury and the ultimate outcome that is kidney failure. Research in this area may identify new pathways or understanding of kidney failure that can be targeted with drugs, that ultimately will help patients with kidney failure.

Research Characteristics

This project includes the following research characteristics:

Digital Health
Wearable Technology
Cost Effectiveness
Budget Impact
Health Technology Assessment
Resource Utilization
Productivity Outcomes
Implementation Science
Health System Integration
Scalability Assessment
Barrier Identification
Patient Reported Outcomes
Real World Evidence
Patient Engagement
Regulatory Pathway
Ethics Focus
Data Sharing
Comorbidity Focus
Social Determinants
Health Equity
Multicenter
Knowledge Translation Focus
Equity Considerations
Safety Focus
Quality of Life
Time to Event
Composite Endpoint
Vulnerable Populations
Combination Therapy
Personalized Medicine
Study Justification

"evaluate the effectiveness of light and fluoxetine in nonseasonal major depression"

Novelty Statement

"investigating effects of light and ion therapy alone and in combination with antidepressant medication for nonseasonal depression"

Methodology Innovation

combination of light therapy with antidepressant medication

Keywords
Cytokines Inflammation Innate Immune System Kidney Disease Kidney Failure Renal Tubular Epithelium